Literature DB >> 16189002

Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus.

Tian-Cheng Li1, Naokazu Takeda, Tatsuo Miyamura, Yoshiharu Matsuura, Joseph C Y Wang, Helena Engvall, Lena Hammar, Li Xing, R Holland Cheng.   

Abstract

Hepatitis E virus (HEV) is a noncultivable virus that causes acute liver failure in humans. The virus's major capsid protein is encoded by an open reading frame 2 (ORF2) gene. When the recombinant protein consisting of amino acid (aa) residues 112 to 660 of ORF2 is expressed with a recombinant baculovirus, the protein self-assembles into virus-like particles (VLPs) (T.-C. Li, Y. Yamakawa, K. Suzuki, M. Tatsumi, M. A. Razak, T. Uchida, N. Takeda, and T. Miyamura, J. Virol. 71:7207-7213, 1997). VLPs can be found in the culture medium of infected Tn5 cells but not in that of Sf9 cells, and the major VLPs have lost the C-terminal 52 aa. To investigate the protein requirement for HEV VLP formation, we prepared 14 baculovirus recombinants to express the capsid proteins truncated at the N terminus, the C terminus, or both. The capsid protein consisting of aa residues 112 to 608 formed VLPs in Sf9 cells, suggesting that particle formation is dependent on the modification process of the ORF2 protein. In the present study, electron cryomicroscopy and image processing of VLPs produced in Sf9 and Tn5 cells indicated that they possess the same configurations and structures. Empty VLPs were found in both Tn5 and Sf9 cells infected with the recombinant containing an N-terminal truncation up to aa residue 125 and C-terminal to aa residue 601, demonstrating that the aa residues 126 to 601 are the essential elements required for the initiation of VLP assembly. The recombinant HEV VLPs are potential mucosal vaccine carrier vehicles for the presentation of foreign antigenic epitopes and may also serve as vectors for the delivery of genes to mucosal tissue for DNA vaccination and gene therapy. The results of the present study provide useful information for constructing recombinant HEV VLPs having novel functions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16189002      PMCID: PMC1235838          DOI: 10.1128/JVI.79.20.12999-13006.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes.

Authors:  Masahiro Niikura; Shiki Takamura; Gisen Kim; Satoru Kawai; Masayuki Saijo; Shigeru Morikawa; Ichiro Kurane; Tian-Cheng Li; Naokazu Takeda; Yasuhiro Yasutomi
Journal:  Virology       Date:  2002-02-15       Impact factor: 3.616

2.  The hepatitis E virus open reading frame 3 protein activates ERK through binding and inhibition of the MAPK phosphatase.

Authors:  Anindita Kar-Roy; Hasan Korkaya; Ruchi Oberoi; Sunil Kumar Lal; Shahid Jameel
Journal:  J Biol Chem       Date:  2004-04-19       Impact factor: 5.157

3.  Expression and self-assembly of empty virus-like particles of hepatitis E virus.

Authors:  T C Li; Y Yamakawa; K Suzuki; M Tatsumi; M A Razak; T Uchida; N Takeda; T Miyamura
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Virus-specific mRNA capping enzyme encoded by hepatitis E virus.

Authors:  J Magden; N Takeda; T Li; P Auvinen; T Ahola; T Miyamura; A Merits; L Kääriäinen
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  The ORF3 protein of hepatitis E virus is a phosphoprotein that associates with the cytoskeleton.

Authors:  M Zafrullah; M H Ozdener; S K Panda; S Jameel
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

6.  Structure of tomato busy stunt virus IV. The virus particle at 2.9 A resolution.

Authors:  A J Olson; G Bricogne; S C Harrison
Journal:  J Mol Biol       Date:  1983-11-25       Impact factor: 5.469

7.  Hepatitis E virus: identification of type-common epitopes.

Authors:  P O Yarbough; A W Tam; K E Fry; K Krawczynski; K A McCaustland; D W Bradley; G R Reyes
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

8.  X-ray crystallographic structure of the Norwalk virus capsid.

Authors:  B V Prasad; M E Hardy; T Dokland; J Bella; M G Rossmann; M K Estes
Journal:  Science       Date:  1999-10-08       Impact factor: 47.728

9.  Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses.

Authors:  E V Koonin; A E Gorbalenya; M A Purdy; M N Rozanov; G R Reyes; D W Bradley
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

10.  Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome.

Authors:  A W Tam; M M Smith; M E Guerra; C C Huang; D W Bradley; K E Fry; G R Reyes
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

View more
  53 in total

1.  Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway.

Authors:  Li Xing; Tian-Cheng Li; Naoyuki Mayazaki; Martha N Simon; Joseph S Wall; Mary Moore; Che-Yen Wang; Naokazu Takeda; Takaji Wakita; Tatsuo Miyamura; R Holland Cheng
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

Review 2.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Structural basis for broad detection of genogroup II noroviruses by a monoclonal antibody that binds to a site occluded in the viral particle.

Authors:  Grant S Hansman; David W Taylor; Jason S McLellan; Thomas J Smith; Ivelin Georgiev; Jeremy R H Tame; Sam-Yong Park; Makoto Yamazaki; Fumio Gondaira; Motohiro Miki; Kazuhiko Katayama; Kazuyoshi Murata; Peter D Kwong
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

4.  Latent infection of a new alphanodavirus in an insect cell line.

Authors:  Tian-Cheng Li; Paul D Scotti; Tatsuo Miyamura; Naokazu Takeda
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

Review 5.  Development of new hepatitis E vaccines.

Authors:  Yufeng Cao; Zhenhong Bing; Shiyu Guan; Zecai Zhang; Xinping Wang
Journal:  Hum Vaccin Immunother       Date:  2018-06-18       Impact factor: 3.452

6.  Chimeric hepatitis E virus-like particle as a carrier for oral-delivery.

Authors:  Pitchanee Jariyapong; Li Xing; Nienke E van Houten; Tian-Cheng Li; Wattana Weerachatyanukul; Benjamin Hsieh; Carlos G Moscoso; Chun-Chieh Chen; Masahiro Niikura; R Holland Cheng
Journal:  Vaccine       Date:  2012-10-26       Impact factor: 3.641

7.  Assessment of the cross-protective capability of recombinant capsid proteins derived from pig, rat, and avian hepatitis E viruses (HEV) against challenge with a genotype 3 HEV in pigs.

Authors:  Brenton J Sanford; Tanja Opriessnig; Scott P Kenney; Barbara A Dryman; Laura Córdoba; Xiang-Jin Meng
Journal:  Vaccine       Date:  2012-08-17       Impact factor: 3.641

8.  Self-assembly of virus-like particles of porcine circovirus type 2 capsid protein expressed from Escherichia coli.

Authors:  Shuanghui Yin; Shiqi Sun; Shunli Yang; Youjun Shang; Xuepeng Cai; Xiangtao Liu
Journal:  Virol J       Date:  2010-07-21       Impact factor: 4.099

9.  Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure.

Authors:  Tetsuo Yamashita; Yoshio Mori; Naoyuki Miyazaki; R Holland Cheng; Masato Yoshimura; Hideaki Unno; Ryoichi Shima; Kohji Moriishi; Tomitake Tsukihara; Tian Cheng Li; Naokazu Takeda; Tatsuo Miyamura; Yoshiharu Matsuura
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-20       Impact factor: 11.205

10.  Structure of the hepatitis E virus-like particle suggests mechanisms for virus assembly and receptor binding.

Authors:  Tom S Y Guu; Zheng Liu; Qiaozhen Ye; Douglas A Mata; Kunpeng Li; Changcheng Yin; Jingqiang Zhang; Yizhi Jane Tao
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.